Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

236
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
236
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

233
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
233
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.9K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.9K
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

243
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
243
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

409
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
409
Equivalence: In Vitro and In Vivo Bioequivalence01:17

Equivalence: In Vitro and In Vivo Bioequivalence

215
Body:Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts.
215

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Learning from the EMA experience: common CMC deficiencies in marketing authorisation applications over the past decade.

Drug discovery today·2025
Same author

Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case Study.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2025
Same author

The Tailored Biosimilar Approach: Expectations and Requirements.

Drugs·2025
Same author

Tofersen for SOD-1-associated amyotrophic lateral sclerosis.

The Lancet. Neurology·2024
Same author

Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2023
Same author

Biomarker-Driven Developments in the Context of the New Regulatory Framework for Companion Diagnostics in the European Union.

Clinical pharmacology and therapeutics·2023

Related Experiment Video

Updated: Jan 19, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.2K

Evolution of the EU Biosimilar Framework: Past and Future.

Elena Wolff-Holz1, Klara Tiitso2, Camille Vleminckx2

  • 1Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, PEI Str 51-58, 63207, Langen, Germany. Elena.Wolff-Holz@pei.de.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|September 22, 2019
PubMed
Summary

The EU

More Related Videos

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

18.2K
Biological Compatibility Profile on Biomaterials for Bone Regeneration
10:28

Biological Compatibility Profile on Biomaterials for Bone Regeneration

Published on: November 16, 2018

13.3K

Related Experiment Videos

Last Updated: Jan 19, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.2K
Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

18.2K
Biological Compatibility Profile on Biomaterials for Bone Regeneration
10:28

Biological Compatibility Profile on Biomaterials for Bone Regeneration

Published on: November 16, 2018

13.3K

Area of Science:

  • Biopharmaceutical regulatory science
  • Drug development and evaluation

Background:

  • European Union (EU) biosimilar approval initially involved cautious regulatory standards.
  • Scientific advancements and experience are refining biosimilar assessment, potentially reducing clinical trial burdens.

Purpose of the Study:

  • To review EU biosimilar approvals, focusing on clinical confirmation beyond analytical and functional data.
  • To analyze the relative importance of different comparability exercise components for biosimilarity determination.

Main Methods:

  • Review of EU guidance documents and European Public Assessment Reports (EPARs) for biosimilars approved via the centralized procedure.
  • Analysis of cases with conflicting comparability data to identify critical elements for biosimilarity.

Main Results:

  • Analytical, functional, and pharmacokinetic similarity are foundational and indispensable for biosimilar approval.
  • Pharmacokinetic similarity is often more sensitive than efficacy trials in detecting product differences, as seen in biosimilar pegfilgrastim cases.
  • Efficacy trials should demonstrate equivalence, with minor uncertainties in increased efficacy potentially acceptable if safety and other data support biosimilarity, but inferior efficacy is not.

Conclusions:

  • The EU regulatory framework for biosimilars is robust and adaptable.
  • It effectively balances stringent regulatory standards, patient safety, and the feasibility of biosimilar development.
  • The framework evolves with scientific knowledge, optimizing requirements for biosimilar assessment.